Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study.
about
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study.
description
2017 nî lūn-bûn
@nan
2017 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Efficacy and safety of ruxolit ...... lts from an independent study.
@ast
Efficacy and safety of ruxolit ...... lts from an independent study.
@en
type
label
Efficacy and safety of ruxolit ...... lts from an independent study.
@ast
Efficacy and safety of ruxolit ...... lts from an independent study.
@en
prefLabel
Efficacy and safety of ruxolit ...... lts from an independent study.
@ast
Efficacy and safety of ruxolit ...... lts from an independent study.
@en
P2093
P2860
P50
P356
P1476
Efficacy and safety of ruxolit ...... lts from an independent study.
@en
P2093
Alessia Tieghi
Antonio Cuneo
Florian H Heidel
Francesco Buccisano
Francesco Cavazzini
Gianni Binotto
Giulia Benevolo
Luigi Scaffidi
Lydia Kallenberg
Marco Spinsanti
P2860
P356
10.1002/HON.2429
P50
P577
2017-05-17T00:00:00Z